IT group wants interoperability standards for drug monitoring

As the House and Senate work in a conference committee on anti-opioid abuse legislation, a coalition called Health IT Now has asked lawmakers to lay out more specific standards on how different states’ prescription drug monitoring programs (PDMPs) will be interoperable.

The Senate’s proposal included a provision to ensure the 49 states that have set up PDMPs are capable of sharing data, in an effort to stop patients from “doctor shopping” across state lines to look for a physician willing to prescribe them potentially addictive opioids.

In a letter to the four legislative leaders in Congress, Health IT Now said Congress should adjust the bill to make sure any data sharing requirements are in line with existing technology and industry standards.

“We are concerned that without clear direction from Congress on how states should implement standards for an interoperable PDMP program, some states may create new and disparate standards for interoperability,” the group wrote. “Likewise, the U.S. Department of Health and Human Services (HHS) could require use of a standard that is not currently used in the market. This would severely harm rapid implementation of an interoperable PDMP and could result in drug seekers circumventing the system, thus failing patients in need of treatment and hurting those who have a valid medical need.”

The group specifically recommended the phrase “widely accepted electronic healthcare standards such as those developed by the National Council of Prescription Drug Programs” be used in the legislation.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.